Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Telaprevir-induced, but not pegylated interferon-associated, retinopathy as a noteworthy adverse effect during triple antiviral therapy in patients with chronic hepatitis C.

Sugawara K, Inao M, Nakayama N, Mochida S.

J Gastroenterol. 2014 Feb;49(2):363-8. doi: 10.1007/s00535-013-0889-8.

PMID:
24081655
2.

KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.

Umemura T, Ota M, Katsuyama Y, Wada S, Mori H, Maruyama A, Shibata S, Nozawa Y, Kimura T, Morita S, Joshita S, Komatsu M, Matsumoto A, Kamijo A, Kobayashi M, Takamatsu M, Yoshizawa K, Kiyosawa K, Tanaka E.

Hum Immunol. 2014 Aug;75(8):822-6. doi: 10.1016/j.humimm.2014.06.003.

PMID:
24929144
3.

Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis.

Bota S, Sporea I, Şirli R, Neghină AM, Popescu A, Străin M.

Clin Drug Investig. 2013 May;33(5):325-31. doi: 10.1007/s40261-013-0074-0. Review.

PMID:
23532802
4.

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.

Itokawa N, Atsukawa M, Tsubota A, Kondo C, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Iwakiri K, Sakamoto C.

J Gastroenterol Hepatol. 2013 Mar;28(3):443-9. doi: 10.1111/jgh.12039.

PMID:
23173698
5.

Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study.

Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group..

Aliment Pharmacol Ther. 2013 Nov;38(9):1076-85. doi: 10.1111/apt.12494.

6.

Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-α2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.

Kawakami Y, Suzuki F, Karino Y, Toyota J, Kumada H, Chayama K.

Antivir Ther. 2014;19(3):277-85. doi: 10.3851/IMP2706.

PMID:
24192751
7.

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H.

Hepatology. 2010 Aug;52(2):421-9. doi: 10.1002/hep.23690.

PMID:
20648473
8.

The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1.

Oze T, Hiramatsu N, Yakushijin T, Yamada R, Harada N, Morishita N, Oshita M, Mita E, Ito T, Inui Y, Inada M, Tamura S, Yoshihara H, Imai Y, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hayashi N, Takehara T.

J Viral Hepat. 2015 Mar;22(3):254-62. doi: 10.1111/jvh.12289.

PMID:
25081140
9.

Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.

Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group..

J Hepatol. 2013 Aug;59(2):205-12. doi: 10.1016/j.jhep.2013.03.020.

PMID:
23542346
10.

Mutational diversity of NS5A and NS3 during triple therapy (telaprevir, pegylated-interferon-α 2b and ribavirin) for genotype 1b chronic hepatitis C: The Kobe Hepatitis Therapeutic Group.

Bai F, Yano Y, Kim SR, Seo Y, Miki A, Saito M, Hirano H, Momose K, Minami A, Hatazawa Y, Hayakumo T, Widasari DI, Rinonce HT, Sugano M, Tani S, Yoon S, Imoto S, Azuma T, Hotta H, Hayashi Y.

Int J Mol Med. 2014 Jun;33(6):1652-6. doi: 10.3892/ijmm.2014.1706.

PMID:
24647743
11.

SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir.

Milazzo L, Peri AM, Mazzali C, Magni C, Calvi E, De Nicolò A, Clementi E, Cheli S, D'Avolio A, Antinori S, Falvella FS.

J Antimicrob Chemother. 2015 Apr;70(4):1155-60. doi: 10.1093/jac/dku519.

PMID:
25583751
12.

Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.

Chen MY, Liu CH, Chen TC, Su TH, Chen PJ, Chen DS, Kao JH, Liu CJ.

J Gastroenterol Hepatol. 2014 Jan;29(1):102-9. doi: 10.1111/jgh.12329.

PMID:
23829453
13.

Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?

Shiffman ML, Esteban R.

Liver Int. 2012 Feb;32 Suppl 1:54-60. doi: 10.1111/j.1478-3231.2011.02718.x. Review.

PMID:
22212573
14.

Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.

Cotte L, Braun J, Lascoux-Combe C, Vincent C, Valantin MA, Sogni P, Lacombe K, Neau D, Aumaitre H, Batisse D, de Truchis P, Gervais A, Michelet C, Morlat P, Vittecoq D, Rosa I, Bertucci I, Chevaliez S, Aboulker JP, Molina JM; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group..

Clin Infect Dis. 2014 Dec 15;59(12):1768-76. doi: 10.1093/cid/ciu659.

PMID:
25139963
15.

Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C.

Atsukawa M, Tsubota A, Shimada N, Abe H, Kondo C, Itokawa N, Nakagawa A, Iwakiri K, Kawamoto C, Aizawa Y, Sakamoto C.

Dig Liver Dis. 2014 Aug;46(8):738-43. doi: 10.1016/j.dld.2014.05.004.

PMID:
24880716
16.

Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients.

Ozeki I, Akaike J, Karino Y, Arakawa T, Kuwata Y, Ohmura T, Sato T, Kamiya N, Yamada I, Chayama K, Kumada H, Toyota J.

J Gastroenterol. 2011 Jul;46(7):929-37. doi: 10.1007/s00535-011-0411-0.

PMID:
21556829
17.

Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.

Kawaoka T, Takahashi S, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Onoe T, Tashiro H, Ohdan H, Chayama K.

J Gastroenterol Hepatol. 2012 Sep;27(9):1467-72. doi: 10.1111/j.1440-1746.2012.07129.x.

PMID:
22432893
18.

Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.

Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group..

J Hepatol. 2013 Oct;59(4):667-74. doi: 10.1016/j.jhep.2013.05.017.

PMID:
23707372
19.

Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study.

Shimada N, Toyoda H, Tsubota A, Ide T, Takaguchi K, Kato K, Kondoh M, Matsuyama K, Kumada T, Sata M.

J Gastroenterol. 2014 Nov;49(11):1485-94. doi: 10.1007/s00535-013-0918-7.

PMID:
24287582
20.

Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.

Buti M, Agarwal K, Horsmans Y, Sievert W, Janczewska E, Zeuzem S, Nyberg L, Brown RS Jr, Hézode C, Rizzetto M, Paraná R, De Meyer S, De Masi R, Luo D, Bertelsen K, Witek J.

Gastroenterology. 2014 Mar;146(3):744-753.e3. doi: 10.1053/j.gastro.2013.11.047.

Supplemental Content

Support Center